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ABSTRACT 
The main aim and objective of the present research work was the design, synthesis, spectral characterization and evaluation of in vitro 
antimicrobial profile of some novel oxadiazole derivatives followed by molecular docking studies against bacterial DNA gyrase. The molecular 
structures of the synthesized compounds were assigned by IR, NMR and Mass spectral analysis. Molecular docking studies were c arried out by 
AUTO DOCK programme. The in vitro antibacterial and antifungal activities were done by paper disk diffusion and agar streak dilution 
technique. In silico molecular docking studies the binding energy  of synthesized compounds (AB1-AB8)  were found to be  -7.66, -7.67, -7.12, -
7.12, -6.59, -6.46, -7.35, -5.09 which indicated that the compound had the high binding affinity towards the  bacterial DNA gyrase with PDB id 
3G7E and inhibit the function  topoisomerase in comparison with standard drug ciprofloxacin (-7.44). The preliminary antimicrobial screening 
displayed that most of the synthesized compounds were executed moderate to good antimicrobial activity against  following bacteria: S. aureus 
(ATCC 9144), B. subtilis (ATCC 6633), S. epidermidis (ATCC 12228), P. Aeruginosa (ATCC27853), E.coli (ATCC25922), V. cholerrae (ATCC14035) and 
fungi:  A. Niger (ATCC 9029), A.flavus (ATCC204304), C. albicans (ATCC10231) and B. dermatitis (ATCC 26199) etc. All the synthesized compounds 
exhibited moderate to good antibacterial and antifungal activity with an MIC range of 12-37µg/ml.  Among these eight synthesized oxadiazole 
derivatives, compound AB1; AB2 and AB7 were found to be very good antibacterial as well as antifungal potentiality with an MIC range of 13-12 
µg/ml; 7-10 µg/ml and 15-18 µg/ml.  
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1. INTRODUCTION 
1. 1. Structural features of Oxadiazole 
Oxadiazoles are a class of heterocyclic aromatic chemical 
compound of the azoles family; with the molecular formula 
C2H2N2O. There are four isomers of oxadiazole depending on 
the position of nitrogen atom in the ring [1]. In chemistry, 
methine is a trivalent functional group =C(−, derived 
formally from methane. It consists of a carbon atom bound 
by two single bonds and one double bond, where one of the 
single bonds is to hydrogen. The group is also called 
methyne or methene; its IUPAC systematic name is 
methylylidene or methanylylidene. Oxadiazole is derived 
from furan by replacement of two methine (-CH=) group by 
two pyridine type nitrogen (-N=) [2]. 1, 3, 4-oxadiazole is a 
five member heterocyclic aromatic compound containing 
two nitrogen atom at position three and four and one oxygen 
atom present at position one. 1, 3, 4 oxadiazole is thermally 
stable than other oxadiazoles, these oxadiazole are very 
important compound in medicinal chemistry due to their 
potential therapeutic efficacy. 
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Table-1:  Structure of different isomers of Oxadiazole 
 
 
 
 
 
1. 2. Physico-chemical properties of 1, 3, 4-Oxadiazole 
 1, 3, 4-oxadiazole is a liquid having boiling point 150ºC.  2, 5-
disubstituted-1, 3, 4-oxadiazole derivatives are colourless 
substances. The lower alkyl derivatives are liquids which 
distil without decomposition. Replacement of an alkyl 
residue by an aryl radical considerably raises the melting 
and boiling points. Usually the asymmetrical 1, 3, 4-
oxadiazole derivatives melt and boil at lower temperature 
than the symmetrical compounds. The solubility of 
oxadiazoles in water varies with the substituent’s present: ʹ, 
5-dimethyl-1, 3, 4-oxadiazole is miscible with water in all 
proportions whereas the solubility of 2, 5-diphenyl-1, 3, 4-
oxadiazole in water is less. Electrophilic introduction of 
functional groups (for example nitro or sulphuric acid 
groups) into the nucleus is unusual.  Electrophilic 
substitution occurs in aryl substituent. Halogenations are 
also difficult, but 2, 5-diaryl-1, 3, 4-oxadiazoles, afford 
complexes with halogens. A range of acylation and alkylation 
reactions of hydroxyl, thio and amino-1, 3, 4-oxadiazoles 
occur at the ring nitrogen [3]. 
1. 3. Chemical properties of 1, 3, 4-Oxadiazole  
1, 3, 4-oxadiazole is a five member heterocyclic aromatic 
compound containing two nitrogen atom at position three 
and four and one oxygen atom present at position one. 1, 3, 
4-oxadiazole is thermally stable than other oxadiazoles, 
these oxadiazoles are very important compound in medicinal 
chemistry due to their potential biological activities. 
Oxadiazole, a very weak base due to inductive effect of the 
extra heteroatom. The replace of two -CH= groups in furan 
by two pyridine type (-N=) lowers aromaticity of resulting 
oxadiazole ring to an extent that the oxadiazole ring exhibit 
character of conjugated diene. The electrophillic 
substitutions in oxadiazole ring are extremely difficult at the 
carbon atom because, the relatively low electron density on 
the carbon atom which can be attributed to electron 
withdrawal effect of the pyridine type nitrogen atom. If 
oxadiazole ring is substituted with electron-releasing groups, 
the attack of electrophiles occurs at nitrogen. The ring is 
generally resistant to nucleophiles attack [4]. 
1. 4. Biological activity  
The extensive literature survey revealed that 1, 3, 4-
oxadiazoles were  reported to possess  a wide range of 
biological activities such as anti inflammatory, anticancer, 
antibacterial, antifungal, anti tubercular, anti-HIV, 
anthelmentic (antimicrobial), anti oxidant,   analgesic and 
anticonvulsant [5-8].  
2. EXPERIMENTAL CHEMISTRY 
2. 1. Materials and method  
2. 1. 1. Chemicals  
The solvents and other chemicals which were used for the 
synthesis and purification of target compounds provided by 
institutional store and were of LR and AR grade. 
2. 1. 2. Synthetic scheme 
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Steps involved in the synthesis of target compounds [9-
10] 
Step 1: Ethyl-4-acetamido phenoxy acetate: A mixture of 
p-acetamido phenol (0.01 mol) and ethyl chloroacetate (0.01 
mol) was refluxed by using dry acetone in presence of 
anhydrous potassium carbonate (K2CO3) for 6hrs. The 
reaction mixture was cooled and then poured in to crushed 
ice. The solid product obtained, these product was filtered, 
dried and recrystallized using ethanol.   
Step 2: 4-Acetamido phenoxy acetyl hydrazide: A mixture 
of ethyl-4-acetamido phenoxy acetate (0.01 mol), hydrazine 
hydrate (0.01 mol) in ethanol (15 ml) was refluxed for 5-8 
hrs. The reaction mixture was cooled and then poured in to 
crushed ice. The solid product was obtained; this product 
was filtered, dried and recrystallized from ethanol. 
Step 3: 2-(4-Acetamidophenoxy methyl) -5-aryl 
substituted - 1, 3, 4-oxadiazole: A mixture of 4-Acetamido 
phenoxy acetyl hydrazide (0.01 mol) and various aromatic 
acids (0.01 mol) in phosphorus oxychloride (10 ml) was 
refluxed for 6-8 hours.  The completion of the reaction 
process was monitored by TLC plates. The contents were 
cooled and poured into the crushed ice and then neutralized 
the reaction mixture with sodium bicarbonate solution and 
the solid product was obtained, the product was filtered, 
dried and recrystallized from ethanol . 
2. 1. 3. Determination of Physicochemical properties 
Melting point: The melting point (or, rarely, liquefaction 
point) of a substance is the temperature at which it changes 
state from solid to liquid. At the melting point the solid and 
liquid phase exists in equilibrium. The melting points of the 
synthesized compounds were determined by open capillary 
tube method.  
Rf value: The retardation factor, Rf is commonly used in 
paper chromatography and thin layer chromatography for 
analyzing and comparing different substances. It can be 
mathematically described by the following ratio. TLC 
method was used to determine the progress of the reaction. 
TLC plates were pre-coated Silica gel (HF254-200 mesh) 
aluminium plates using ethyl acetate: n-hexane are used as 
solvent and visualized under UV- chamber.                                                                       
Solubility profile: Solubility is the property of a solid, liquid 
or gaseous chemical substance called solute to dissolve in a 
solid, liquid or gaseous solvent. The solubility of a substance 
fundamentally depends on the physical and chemical 
properties of the solute and solvent as well as on 
temperature, pressure and presence of other chemicals 
(including changes to the pH) of the solution. 
Percentage yield (%): The theoretical yield is an organic 
reaction is the weight of the product which would be 
obtained if the reaction had proceeded to completion 
according to the chemical equation. The yield is the weight 
of pure product which is isolated from the reaction. The 
percentage yield may be expressed as:                                                       
2. 1. 4. Spectral analysis 
Functional group determination 
The IR spectra of the synthesized compounds were recorded 
on ABB Bomen FT-IR spectrometer MB 104 IR spectra with 
potassium bromide pellets. 
Determination of number of protons 
The number of protons present in each synthesized 
compounds were determined   by BRUKER NMR 
spectrometer (1H-NMR) in DMSO. TMS was used as an 
internal standard. 
Determination of molecular weight 
The Mass spectra of synthesized compounds were recorded 
by JEOL GCmate. Mass spectroscopy mainly used to 
determine the molecular weight of the synthesized 
compounds. The IR, 1H-NMR and MASS spectra are used to 
assign the structure of synthesized compounds. 
3. COMPUTATIONAL CHEMISTRY 
3. 1. Molecular docking [11] 
 Computational chemistry is a branch of chemistry that uses 
computer simulation to assist in solving chemical problems. 
It uses methods of theoretical chemistry, incorporated into 
efficient computer programs, to calculate the structures and 
properties of molecules and solids. Molecular docking is 
defined as an optimization problem, which would describe the ǲbest-fitǳ orientation of a ligand that binds to a particular 
protein of interest. During the course of the process, the 
ligand and the protein adjust their conformation to achieve 
an overall ǲbest-fitǳ and this kind of conformational 
adjustment resulting in the overall binding is referred to as ǲinduced fit. The aim of the molecular docking to achieve an 
optimized conformation for both the protein and the ligand 
and to achieve relative orientation between protein and 
ligand such that free energy of overall system is minimized. 
The application of docking are the hit identification docking 
combined with a scoring function can be used to quickly 
screen large databases of potential drugs in silico to identify 
molecules that are likely to bind to protein target of interest 
and the lead optimization docking can be used to predict in 
where and in which relative orientation a ligand binds to a 
protein. This information may in turn be used to design 
more potent and selective analogues. 
 
 
Fig-1-A: Elements in molecular docking 
Bhaumik et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4):438-453 
  
ISSN: 2250-1177                                                                                  [441]                                                                                 CODEN (USA): JDDTAO 
3. 2. Posing and scoring function of docking [12]  
Posing the process of determining whether a given 
conformation and orientation of a ligand fits the active site. 
This is usually a fuzzy procedure that returns many 
alternative results. pose score is a measure of the fit of a 
ligand into the active site. Scoring during the posing phase 
usually involves simple energy calculations (Vdw + H-bond + 
dE = Vender walls + Hydrogen bond + Dessolve energy.  EE= 
Electrostatic Energy. TIME = Total Intermolecular Energy). 
One early general-purposed empirical scoring function to 
describe the binding energy of ligands to receptors was 
developed by Böhm. This empirical scoring function took the 
form:
                ∑               ∑                         | |            
A more general thermodynamic "master" equation is as follows: 
                 [      ][        ][       ]                                                              
 
3. 3. Requirements 
Purpose: Computational Analysis. Job Id: 
NRS/008/10/2016. PDB Code: 3G7E. Soft ware used: Auto 
Dock 4. 
Structure of bacterial DNA gyrase (E. coli gyrase B) 
Crystalline structure of the target protein Topoisomerase 
bacterial DNA gyrase with PDB id 3G7E was retrieved from 
protein data bank and protein clean-up process was done 
and essential missing hydrogen atom were been added. 
Different orientation of the lead molecules AB1 to AB8 along 
with standard drug ciprofloxacin with respect to the target 
protein was evaluated by Auto dock program and the best 
dock pose was selected based on the interaction study 
analysis.
 
 
Fig-1-B: Structure of bacterial DNA gyrase 
 
4. EXPERIMENTAL MICROBIOLOGY 
4. 1. Microorganisms 
The standard strains (American type culture collection, 
ATCC, USA, Rockville) and the pathological strains were 
supplied from the department of Pharmaceutical 
Microbiology & Biotechnology, Anurag Pharmacy College, 
Kodad, Nalgonda, T. S, India. The antimicrobial activity of the 
synthesized compounds was screened by using against the 
following bacteria and fungi. 
A. Bacteria: Gram positive: S. aureus (ATCC 9144), B. subtilis 
(ATCC 6633), S. epidermidis (ATCC 12228). Gram negative: P. 
Aeruginosa (ATCC27853), E.coli (ATCC25922), V. cholerrae 
(ATCC14035) 
B. Fungi: A. Niger (ATCC 9029), A. flavus (ATCC204304), C. 
albicans (ATCC10231) and B. dermatitis (ATCC 26199) etc. 
4. 2. Chemicals and drugs 
DMF was used as solvent and Ciprofloxacin (antibacterial 
and Ketaconazole (antifungal) were used as standard 
antimicrobial drugs. 
4. 3. Procedure 
Preparation of nutrient agar medium [13-14] 
 Nutrient agar medium is one of the most commonly used 
medium for several routine bacteriological purposes: 
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Table-2-A: Composition of Nutrient agar medium for bacterial growth 
S. l No. Ingredients     Grams/Litter 
1. Peptone 10 gm 
2. Beef extract 10 gm 
3. Agar 20 gm 
4. Sodium chloride 5.0 gm 
5. Distilled water 1000 ml 
6. PH 7.0 
 
Table-2-B: Composition of Sabouraud dextrose agar medium for fungal growth 
S. l No. Ingredients     Grams/Litter 
1. Glucose 20 gm 
2. Peptone 10 gm 
3. Agar 20 gm 
4. Distilled water 1000 ml 
5. PH 5.4  
 
All the ingredients were added to distilled water and boiled 
to dissolve all the ingredients in medium completely. The 
medium sterilized by autoclaving at 15 lbs pressure. 
Temperature was maintained at 1210C for 15 minutes. 
Preliminary screening of anti-bacterial activity by paper 
disc diffusion method [15] 
 The sterilized (autoclaved at 120o C for 30 min) medium 
was inoculated (1mL/100 ml of medium) with the 
suspension [105 cfu m/l (colony forming unit per millilitre)] 
of the microorganism (matched to McFarland barium 
sulphate standard) and poured in Petri dish to give a depth 
of 3-4mm. The paper impregnated with the test compounds 
(50, 100,150 µg/ml in dimethyl formamide) was placed on 
the solidified medium. The plates were pre-incubated for 
1hour at RT and incubated at 37 oC for 24 hours for anti-
bacterial and antifungal activities respectively. Ciprofloxacin 
(100 µg/disc) and ketoconazoloe (100 µg/disc) was used as 
a standard. The observed zone of inhibition was compared 
with standard drug. 
Determination of MIC [14 and 16] 
MIC of the synthesized compounds was determined by agar 
streak dilution method. A stock solution of the synthesized 
compounds (100 µg/ml) in dimethyl formamide was 
prepared and graded quantities of the test compounds were 
incorporated in specified quantities of molten nutrient agar 
medium. A specified quantity of the medium containing the 
compounds was poured into a Petri dish to give a depth of 3-
4mm and allowed to solidify. Suspension of the 
microorganism were prepared to contain approximately105 
cfu m/l and applied or spread on surface of agar medium. All 
plates were incubated at 37o C 2 to 3 days for bacterial and 
fungal growth.  The MIC was considered to be the lowest 
concentration of the test substance exhibiting no visible 
growth of bacteria on the plate. 
  
 
5. RESULTS  
Table-3: Represents the list of synthesized oxadiazole derivatives 
Sl. No. Compound codes.   
 
R 
1. AB1 4-NH
2
 
2. AB2 2, 4-di-Cl 
3. AB3 4-F 
4. AB4 2-Br 
5. AB5 2-Br, 4-NO2 
6. AB6 4-NO2 
7. AB7 3, 5-di-NO2 
8. AB8 2-OH, 3, 5-di-NO2 
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Table 4:  Physicochemical properties of synthesized compounds 
Sl. No. Compounds code M. F M. Wt Rf value m. p Yield 
1. AB1 C17H16N4O3 324.33 0.77 116-119 0C 74.5 %. 
2. AB2 C17H13Cl2N3O3 378.209 0.74 180-183 0C 69.9% 
3. AB3 C17H14FN3O3 327.309 0.75 189-193 0C 74% 
4. AB4 C17H14BrN3O3 388.215 0.65 183-186 0C 69% 
5. AB5 C17H13BrN4O5 433.213 0.64 166-163 0C 60% 
6. AB6 C17H14N4O5 354.31 0.72 171-175 0C 64% 
7. AB7 C17H13N5O7 399.31 0.68 199-204 0C 78% 
8. AB8 C17H13N5O8 415.31 0.72 212-2150C 68% 
 
Spectral data of synthesized compounds 
Compound AB1  
N-(4-{[5-(4-aminophenyl)-1, 3, 4-oxadiazol-2-yl]methoxy}phenylȌ acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3393.16 
cm-1 (Ar-NH), 1633.67 cm-1 (C=N), 1575.88 cm-1 (C=C), 
1069.05 cm-1 (-C-O-C-), 3132.54 cm-1 (Ar-CH), 1249.43 cm-
1(Ar-NH2), 1H-NMR δ ȋppmȌ: ͸.Ͷͷ-7.4 (s, 8H, Ar-H), 5.17 (s, 
2H,-CH2), 4.1(s, 2H, -NH2), 2.05 (s,1H, -CH3), 8.05 (s, 1H, -NH), 
Mass (m/e value) % relative abundance: 324.12 (M+) (5.1), 
310.87 (4) , 296.22 (8.25), 282.76 (2.2), 272.38(2.32), 
262.6432 (7.3), 248.34 (11), 217.12 (15), 207.14 (7), 116.67 
(18), 58.33(B). 
Compound AB2 
N-(4-{[5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenylȌ acetamide.. )R ȋKBrȌ ɋ ȋcm-1): 3381.92 
cm-1 (Ar-NH), 1673.42 cm-1 (C=N), 1545.03 cm-1 (C=C), 
1085.04 cm-1 (-C-O-C-), 687.47 cm-1 (C-Cl), 3115.62 cm-1 (Ar-
CH), 1H-NMR δ ȋppmȌ: ͸.͸-7.82(s, 8H, Ar-CH), 2.5 (s, 3H, -
CH3), 8.03(s, 1H, -NH), 5.22(s, 2H, -CH2), Mass (m/e value) % 
relative abundance: 377.03 (M+) (2.8), 333.16 (1.5), 325.42 
(2.7), 286.43 (2.6), 183.26 (6), 160.62 (7), 140.65 (16), 
115.64 (33),  95.53 (B). 
Compound AB3  
N-(4-{[5-(4-flurophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenylȌ acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3392.09 
cm-1 (Ar-NH), 1617.53 cm-1 (C=N), 1528.16 cm-1 (C=C), 
1093.52 cm-1 (-C-O-C-), 1371.78 cm-1 (C-F),  3114.61 cm-1 
(Ar-CH), 1H-NMR δ ȋppmȌ: ʹ.ʹͳ ȋs, ͳ(, -CH3), 8.09 (s, 1H, -
NH), 5.21(s, 1H, -CH2), 6.7-8.01(m, 8H, Ar-CH), Mass (m/e 
value) % relative abundance: 327.10 (M+) (6.3), 310.37 (2.3), 
299.57 (3), 282.87 (3.9), 266.22 (5), 249.61 (1.2), 232.72 (4), 
104.86 (8.1),  75.50 (B). 
Compound AB4  
N-(4-{[5-(2-bromophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenylȌ acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3286.82 
cm-1 (Ar-NH), 1617.53 cm-1 (C=N), 1528.16 cm-1 (C=C), 
1093.52 cm-1 (-C-O-C-), 687.47 cm-1 (C-Br),  3114.61 cm-1 
(Ar-CH), 1H-NMR δ ȋppmȌ: ʹ.ʹͳ ȋs, ͳ(, -CH3), 8.09(s, 1H, -
NH), 5.21(s, 1H, -CH2), 6.7-8.01(m, 8H, Ar-CH), Mass (m/e 
value) % relative abundance: 387.02(M+) (6.3), 310.37 (2.3), 
299.57 (3), 282.87 (3.9), 266.22 (5), 249.61 (1.2), 232.72 (4), 
104.86 (8.1),  75.60 (B). 
Compound AB5  
N-(4-{[5-(2-bromo,4-nitrophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenylȌ acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3381.95 
cm-1 (Ar-NH), 1684.44 cm-1 (C=N), 1586.2 cm-1 (C=C), 
1064.25 cm-1 (-C-O-C-), 1365.57 cm-1(N=O), 619.89 cm-1 (C-
Br), 3130.43 cm-1 (Ar-CH), 1H-NMR δ ȋppmȌ: ͸.͹Ͷ-8.36(m, 
7H, Ar-CH) ,5.31(s, 2H, -CH2),2.31 (s, 1H, -CH3), 8.16(s, 1H, -
NH), Mass (m/e value) % relative abundance: 432.00 (M+) 
(4), 388.71 (8.1), 362.27 (4.2), 233.28 (5), 217.31 (8.9), 
182.52 (5), 96.79 (7), 78.82(B). 
Compound AB6  
N-(4-{[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]methoxy}phenylȌacetamide. )R ȋKBrȌ ɋ ȋcm-1): 3382.43 
cm-1 (Ar-NH), 1703.01 cm-1 (C=N), 1592.32 cm-1 (C=C), 
1088.54 cm-1 (-C-O-C-), 1378.11 cm-1 (N=O), 3112.69 cm-1 
(Ar-CH), 1H-NMR δ ȋppmȌ: ͸.Ͷͳ-7.8(m, 8H, Ar-CH), 2.42 (s, 
3H, -CH3), 8.13(s, 1H, -NH), 5.21(s, 2H, CH2), Mass (m/e 
value) % relative abundance: 354.09 (M+) (3.8), 335.16 (4.8), 
302.39 (3.1), 287.43 (3.7), 249.58 (7.1), 226.00 (5.8), 204.96 
(6.7), 127.56 (13.1), 103.69 (9),   89.93 (B). 
Compound AB7 
N-(4-{[5-(3,5-dinitrophenyl)-1,3,4-oxadiazol-2-
yl]methoxy}phenyl) acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3382.02 
cm-1 (Ar-NH), 1677.79 cm-1 (C=N), 1530.6 cm-1 (C=C), 
1089.68 cm-1 (-C-O-C-), 1372.45 cm-1 (N=O),  1523.12 asym 
cm-1 (N=O), 3117.5 cm-1 (Ar-CH), 1H-NMR δ ȋppmȌ: ͸.ͺ͵-
8.42(m, 8H, Ar-CH), 5.35(s, 2H,-CH2), 2.07 (s, 1H,- CH3), 8.24 
(s, 1H, -NH), Mass (m/e value) % relative abundance: 399.08 
(M+) (5), 388.76 (13), 380.25 (8), 261.63 (8), 182.52 (5), 
167.62 (17), 156.56 (19), 81.97(B). 
Compound AB8 
N-(4-{[5-(2-hydroxy-3,5-dinitrophenyl)-1,3,4-oxadiazol-2-
yl]methoxy}phenyl) acetamide. )R ȋKBrȌ ɋ ȋcm-1): 3118.84 
cm-1 (Ar-NH), 1654.42 cm-1 (C=N), 1541.89. cm-1 (C=C), 
1368.45 cm-1 (N=O), 1528.45 asym. cm-1 (N=O),1090.01 cm-
1 (-C-O-C-), 3118.84 cm-1 (Ar-CH), 3382.83 cm-1(Ar-OH), 1H-NMR δ ȋppmȌ: ͸.͹-7.6(s, 6H, Ar-CH), 2.11 (s, H, -CH3), 8.00(s, 
1H, -NH), 5.12(s, 1H, -CH2), Mass (m/e value) % relative 
abundance: 415.07(M) (11.1), 318.68 (16), 292.76 (7), 
276.89 (20), 249.99 (8.2), 236.0277 (28.1), 203.2266 (76), 
182.2587 (8), 134.4966 (32), 116.55 (B) 
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Table-5: Docking results analysis 
C. C EFEB 
(k.cal/mol) 
EIC (Ki) 
uM 
vdw+H-bond+de 
(k.cal/mol) 
EE 
(k.cal/mlo) 
TIME 
(k.cal /mol) 
Fr (%) IS 
AB1 -7.66 2.43 -9.16 -0.22 -9.37 50 859.57 
AB2 -7.67 2.40 -9.08 +0.05 -9.04 50 937.679 
AB3 -7.12 6.03 -8.71 -0.20 -8.91 100 907.998 
AB4 -7.12 6.00 -8.54 +0.13 -8.41 50 824.232 
AB5 -6.59 14.77 -8.70 +0.10 -8.60 50 920.18 
AB6 -6.46 18.24 -7.89 -0.21 -8.10 50 917.303 
AB7 -7.35 4.10 9.70 -0.04 -9.74 50 928.775 
AB8 -5.09 187.23 -7.79 +0.46 -7.32 100 909.889 
Ciprofl
oxacin 
-7.44 -3.51 7.26 -1.21 -8.47 50  850.017 
C. C = Compounds code. EFEB = Est. Free Energy of Binding. EIC = Est. Inhibition Constant. Vdw + H-bond + dE = Vender walls + Hydrogen bond 
+ Dessolve energy.  EE = Electrostatic Energy. TIME = Total Intermolecular Energy. Fr = Frequency. IS = Interaction Surface.  
AB1 WITH 3G7E BACTERIAL DNA GYRASE 
 
AB2 WITH 3G7E -BACTERIAL DNA GYRASE 
 
INTERACTION STUDY 
 
INTERACTION STUDY 
 
RECEPTOR LIGAND COMPLEX 
 
RECEPTOR LIGAND COMPLEX 
  
Fig-2-A: MD of Compound AB1 and AB2 against bacterial DNA gyrase. 
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AB3 WITH 3G7E BACTERIAL DNA GYRASE 
 
AB4 WITH 3G7E BACTERIAL DNA GYRASE 
 
INTERACTION STUDY 
 
INTERACTION STUDY 
 
RECEPTOR LIGAND COMPLEX 
 
RECEPTOR LIGAND COMPLEX 
 
Fig-2-B: MD of Compound AB3 and AB4 against bacterial DNA gyrase. 
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AB5 WITH 3G7E BACTERIAL DNA GYRASE 
 
AB6 WITH 3G7E BACTERIAL DNA GYRASE 
 
INTERACTION STUDY 
 
INTERACTION STUDY 
 
RECEPTOR LIGAND COMPLEX 
 
RECEPTOR LIGAND COMPLEX 
 
Fig-2-C: MD of Compound AB5 and AB6 against bacterial DNA gyrase. 
 
 
 
 
Bhaumik et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(4):438-453 
  
ISSN: 2250-1177                                                                                  [447]                                                                                 CODEN (USA): JDDTAO 
AB7 WITH 3G7E BACTERIAL DNA GYRASE 
 
AB8 WITH 3G7E BACTERIAL DNA GYRASE 
 
INTERACTION STUDY 
 
INTERACTION STUDY 
 
RECEPTOR LIGAND COMPLEX 
 
RECEPTOR LIGAND COMPLEX 
 
Fig-2-D: MD of Compound AB7 and AB8 against bacterial DNA gyrase. 
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Table-6-A: Zone of inhibition of synthesized compounds (AB1-AB8) against Gram positive bacteria 
C. C 
 
BACTERIA 
S. aureus B. subtilis S. epidermidis 
Concentration ȋμg/mlȌ 
50 100 150 50 100 150 50 100 150 
Zone of inhibition in mm 
AB1 7.4 12.3 10.1 9.1 10.9 9.1 7.5 11.6 8.7 
AB2 7.6 12.8 8.4 7.1 11.4 9.4 7.9 13.1 10.4 
AB3 6.7 11.2 8.1 6.5 10.4 8.1 6.3 10.4 7.9 
AB4 6.2 10.2 6.9 5.0 9.5 6.9 6.1 8.8 7.1 
AB5 5.6 8.6 6.5 5.2 8.2 6.7 5.2 8.0 6.3 
AB6 5.4 7.8 9.5 5.2 8.0 6.3 5.0 7.1 6.3 
AB7 7.2 11.9 6.4 6.5 10.6 8.4 7.0 11.0 8.3 
AB8 5.3 7.8 7.1 5.2 7.5 6.2 5.0 8.1 6.1 
Ciprofloxac
in 
Concentration ȋͳͲͲ μgm/mlȌ 
28.9 24.4 26.8 
 
Table-6-B: Zone of inhibition of synthesized compounds (AB1-AB8) against Gram negative bacteria 
C. C 
 
BACTERIA 
E. coli P. aeruginosa V. cholerae 
Concentration ȋμg/mlȌ 
50 100 150 50 100 150 50 100 150 
Zone of inhibition in mm 
AB1 7.2 11.4 10.4 6.4 10.7 8.8 7.3 11.3 8.4 
AB2 7.3 11.6 10.8 6.9 11.0 9.0 7.5 12.8 10.0 
AB3 6.5 10.9 10.2 6.0 10.0 7.8 6.3 10.4 7.5 
AB4 6.2 10.5 9.2 5.0 9.5 6.9 6.1 8.8 7.1 
AB5 5.5 7.5 6.9 5.3 8.3 6.8 5.3 8.2 6.4 
AB6 5.3 7.6 6.2 5.2 7.9 6.1 5.1 7.2 5.7 
AB7 7.0 11.0 10.9 6.1 10.3 8.1 6.9 11 8.0 
AB8 5.1 7.4 6.0 5.0 7.5 6.0 5.0 8.0 6.0 
Ciprofloxac
in 
Concentration ȋͳͲͲ μgm/mlȌ 
28.5 24 26.4 
  
 
 
Fig 3-A(1): Zone of inhibition of bacteria by test compounds. 
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Fig 3-A(2): Zone of inhibition of bacteria by test compounds. 
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Table-6-C: Zone of inhibition of synthesized compounds (AB1-AB8) against fungi. 
 
 
 
 
Fig 3-B: Zone of inhibition of fungi by test compounds 
C. C 
 
FUNGI 
A. niger C. albicans B. dermatitis 
Concentration ȋμg/mlȌ 
50 100 150 50 100 150 50 100 150 
Zone of inhibition in mm 
AB1 7.1 11.4 9.4 6.3  9.9 8.2 6.9  11.3 8.7 
AB2 7.3 11.9 9.7 6.8 10.2 8.4 7.1 11.9 9.2 
AB3 6.5 10.0 8.2 5.6 9.0 7.2 5.5 9.3 7.5 
AB4 6.0  9.6 7.8 5.0 8.8 6.4 5.2 8.7 7.2 
AB5 5.5  8.7 6.9 5.3 8.3 6.3 5.3 8.2 6.8 
AB6 5.3 7.6  6.2 5.2 7.9 6.1 5.1 7.2 5.9 
AB7 6.9 10.6 8.8 5.8 9.3 7.5 5.8 9.8 7.9 
AB8 5.1 7.4 6.4 5.0 7.5 6.2 5.0 8.3 6.4 
Ketoconazo
le 
Concentration ȋͳͲͲ μgm/mlȌ 
28 29 27 
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Table-7-A Minimum inhibitory Concentration (MIC) of Synthesized compounds against Gram positive bacteria 
C.C BACTERIA 
S. aureus B. subtilis S. epidermidis 
Concentration ȋμgm/mlȌ 
AB1 12 13 12 
AB2 7 8 10 
AB3 22 23 20 
AB4 25 26 22 
AB5 27 28 30 
AB6 30 32 33 
AB7 17 18 17 
AB8 33 37 37 
Ciprofloxacin 0.2 0.2 0.2 
 
Table-7-B: Minimum inhibitory Concentration (MIC) of Synthesized Compounds against Gram negative bacteria 
C.C BACTERIA 
E. coli P. aeruginosa V. cholerae 
Concentration ȋμg/mlȌ 
AB1 13 12 12 
AB2 8 7 10 
AB3 23 22 20 
AB4 22 26 22 
AB5 28 27 30 
AB6 30 32 33 
AB7 15 18 17 
AB8 37 33 37 
Ciprofloxacin 0.3 0.3 0.3 
 
Table-7-C: Minimum Inhibitory Concentration (MIC) of Synthesized Compounds against fungi 
C.C FUNGI 
A. niger C. albicans B. dermatitis 
Concentration ȋμgm/mlȌ 
AB1 12 12 13 
AB2 10 7 8 
AB3 20 22 23 
AB4 25 26 26 
AB5 30 27 28 
AB6 33 32 35 
AB7 17 18 18 
AB8 35 33 37 
Ketoconazole 5 5 5 
 
 
Fig-4A: MIC of synthesized compounds against different bacteria. 
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Fig-4-B: MIC of synthesized compounds against different fungi 
 
6. DISCUSSION 
6. 1. Experimental chemistry 
An Rf value was characteristic for any given compound 
(provided that the same stationary and mobile phases are 
used). It provided corroborative evidence as to the identity 
of the new synthetic compound. Rf values of synthesized 
compounds indicated the reaction was proceeded in right 
direction and purity of new synthetic derivatives (AB1-AB8). 
The synthetic procedure of oxadiazole derivatives was found 
to have satisfactory yield. All the synthesized compounds 
were found to be insoluble in water, slightly soluble in 
Chloroform, ethanol and freely soluble in DMF, DMSO. The 
spectral analysis confirmed the successful synthesis of 
desired compounds.  
6. 2. Computational chemistry 
Most of the scoring functions in molecular docking are 
physics based molecular mechanics force fields that estimate 
the energy of the binding pose; a low (negative) energy 
indicates a stable system and thus a likely binding 
interaction. Molecular docking is performed to find out the 
binding affinity or molecular interaction energy (kcal/mol) 
of docked compounds. Lowest (negative value) energy of 
docked molecule indicates high binding affinity with the 
target protein/compound. In silico molecular docking 
studies the binding energy  of synthesized compounds (AB1-
AB8)  were found to be  -7.66, -7.67, -7.12, -7.12, -6.59, -6.46, 
-7.35, -5.09 which indicated that the compound had high 
binding affinity towards the  bacterial DNA gyrase 
(topoisomerase) with PDB id 3G7E and inhibit the function  
topoisomerase in comparison with standard drug 
ciprofloxacin (-7.44). 
6. 3. Experimental microbiology 
(i) Synthesized compounds were (50, 100 and 150 Ɋg/ml) 
screened for antimicrobial activity by paper disc diffusion 
method.  From the data shown in table the observations 
were made as followed:  Most of the synthesized compounds executed moderate 
to good antimicrobial activity against the tested 
microorganisms. 
 When compared to standard drug ciprofloxacin, 
compounds AB2, AB1, AB7, AB3, AB4 were found to 
exhibit good Antibacterial activity.  When compared to standard drug ketoconazole, 
compounds AB2, AB1, AB7, AB3, AB4 and AB8 were 
found to exhibit good antifungal activity. 
(ii) The MIC of synthesized compounds was screened by agar 
streak dilution method and from the experimental data the 
following observation was made:  All the synthesized compounds exhibited moderate to 
good antibacterial and antifungal activity with an MIC 
range of 12-37µg/ml.   Among these eight synthesized oxadiazole derivatives, 
compound AB1; AB2 and AB7 were found to be very 
good antibacterial as well as antifungal potentiality 
with an MIC range of 13-12 µg/ml; 7-10 µg/ml and 15-
18 µg/ml. 
7. CONCLUSION 
Here we concluded that the compound AB2, AB1, AB7, AB3, 
AB4 and AB8 possessed potential antimicrobial activity 
against following bacteria: S. aureus (ATCC 9144), B. subtilis 
(ATCC 6633), S. epidermidis (ATCC 12228), P. Aeruginosa 
(ATCC27853), E.coli (ATCC25922), V. cholerrae (ATCC14035) 
and fungi:  A. Niger (ATCC 9029), A.flavus (ATCC204304), C. 
albicans (ATCC10231) and B. dermatitis (ATCC 26199) etc. 
The antibacterial potentiality of synthesized compounds 
were correlated with in silico molecular docking studies 
which was also proved molecular interaction of the 
compounds with the target protein bacterial DNA gyrase for 
their binding affinity and known to be inhibitors for bacterial 
DNA gyrase. 
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